Mind + Muscle

technical minds + legal muscle

Sterne Kessler Goldstein Fox
Lori M. Brandes, Ph.D.

Mind + Muscle

Lori M. Brandes, Ph.D.

Of Counsel


Dr. Brandes is Of Counsel in the firm's Biotechnology/Chemical Group where she counsels domestic and international clients on the preparation, prosecution, and management of complex worldwide patent portfolios. She is also experienced in technology transfer, invalidity, noninfringement, freedom-to-operate and patentability opinions, and due diligence investigations.  Specifically, she works with clients to obtain and enforce patents in areas such as biotechnology, immunology, biofuels, pharmaceutical formulations, and food science.  Dr. Brandes has also been involved in U.S. patent interference and litigation matters, as well as foreign oppositions.  

During her graduate studies, Dr. Brandes was awarded fellowships from the Washington Metropolitan Chapter of the Achievement Rewards for College Scientists and from the U.S. Army Medical Research and Material Command.  Her research concentrated on the role of the transcription factor NF-kappaB in the development of tumor drug resistance.

Dr. Brandes’ areas of technical expertise include:

  • Cell and Molecular Biology
  • Recombinant DNA techniques
  • Gene expression profiling
  • Cellular stress pathways
  • Pharmacology
  • Cancer chemotherapy
  • Drug resistance

Dr. Brandes is a contributing author of Patent Office Litigation, Second Edition, published in 2017, and the two-volume set Patent Office Litigation, published in 2012 by Thomson Reuters Westlaw. The first edition focused on the new contested proceedings under the America Invents Act that year, while the second edition provides a fresh and comprehensive exploration of these proceedings. Both books examine how the proceedings interact with other aspects of patent procurement and enforcement, and deliver practical analysis and advice.

Technical Publications

Brandes LM, Lin ZP, Patierno SR, Kennedy KA.  Reversal of physiological stress-induced resistance to topoisomerase II inhibitors using an inducible phosphorylation site-deficient mutant of IkappaBalpha. Mol. Pharmacol. 60:559-67, 2001

Boller YC, Brandes LM, Russell RL, Lin ZP, Patierno SR, Kennedy KA.  Prostaglandin A1 inhibits stress-induced NF-kappaB activation and reverses resistance to topoisomerase II inhibitors. Oncol. Res. 12:383-95, 2000

  • Admissions
      • District of Columbia

      • United States Patent and Trademark Office

  • Education
    • J.D., University of Maryland

    • Ph.D., Pharmacology, The George Washington University

    • B.A., Biochemistry and Molecular, Cellular and Developmental Biology, University of Colorado


    Unsolicited e-mails and information sent to Sterne, Kessler, Goldstein & Fox P.L.L.C. will not be considered confidential or privileged, may be disclosed to others, may not receive a response, and do not create an attorney-client relationship with Sterne Kessler.  If you are not already a client of Sterne Kessler, do not include any confidential information in this message.